39,024 Shares in Bioverativ Inc (BIVV) Acquired by Pictet Asset Management Ltd.
Pictet Asset Management Ltd. acquired a new stake in shares of Bioverativ Inc (NASDAQ:BIVV) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 39,024 shares of the biotechnology company’s stock, valued at approximately $2,227,000.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. TCI Wealth Advisors Inc. acquired a new position in Bioverativ during the third quarter valued at approximately $186,000. Reliance Trust Co. of Delaware acquired a new position in Bioverativ during the third quarter valued at approximately $249,000. Whittier Trust Co. of Nevada Inc. acquired a new position in Bioverativ during the third quarter valued at approximately $293,000. Raymond James Trust N.A. acquired a new position in Bioverativ during the third quarter valued at approximately $297,000. Finally, Oakbrook Investments LLC acquired a new position in Bioverativ during the third quarter valued at approximately $327,000. Institutional investors and hedge funds own 95.16% of the company’s stock.
BIVV has been the subject of several research analyst reports. Zacks Investment Research upgraded shares of Bioverativ from a “hold” rating to a “strong-buy” rating and set a $73.00 price objective for the company in a research report on Tuesday, July 25th. Cowen and Company reiterated a “buy” rating and set a $80.00 price target on shares of Bioverativ in a report on Friday, August 4th. Royal Bank Of Canada initiated coverage on shares of Bioverativ in a report on Thursday, September 14th. They set a “sector perform” rating and a $59.00 price target for the company. Evercore ISI initiated coverage on shares of Bioverativ in a report on Wednesday, August 16th. They set an “in-line” rating and a $58.00 price target for the company. Finally, Argus upgraded shares of Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a report on Wednesday, September 20th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Bioverativ presently has an average rating of “Hold” and an average target price of $61.73.
ILLEGAL ACTIVITY WARNING: “39,024 Shares in Bioverativ Inc (BIVV) Acquired by Pictet Asset Management Ltd.” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/11/14/39024-shares-in-bioverativ-inc-bivv-acquired-by-pictet-asset-management-ltd.html.
Shares of Bioverativ Inc (BIVV) opened at $53.91 on Tuesday. Bioverativ Inc has a one year low of $40.00 and a one year high of $64.41.
Bioverativ (NASDAQ:BIVV) last issued its quarterly earnings data on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.25. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. The company had revenue of $291.60 million for the quarter, compared to analysts’ expectations of $285.45 million. The business’s quarterly revenue was up 27.2% on a year-over-year basis. research analysts anticipate that Bioverativ Inc will post 2.45 earnings per share for the current fiscal year.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Stock Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related stocks with our FREE daily email newsletter.